In vitro efficacy of Artemisia extracts against SARS-CoV-2
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Traditional medicines based on herbal extracts have been proposed as affordable treatments for patients suffering from coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Teas and drinks containing extracts of Artemisia annua and Artemisia afra have been widely used in Africa in efforts to prevent and fight COVID-19 infections. We sought to study the ability of different A. annua and A. afra extracts and the Covid-Organics drink produced in Madagascar to inhibit SARS-CoV-2 and feline coronavirus (FCoV) replication in vitro. Several extracts as well as Covid-Organics inhibit SARS-CoV-2 and FCoV replication at concentrations that did not affect cell viability. It remains unclear whether peak plasma concentrations in humans can reach levels needed to inhibit viral replication following consumption of teas or Covid-Organics. Clinical studies are required to evaluate the utility of these drinks for COVID-19 prevention or treatment in patients.
Article activity feed
-
SciScore for 10.1101/2021.02.14.431122: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Plaques of FCoV were stained with specific antibodies (primary antibody: mouse anti feline coronavirus monoclonal antibody at 1:500 dilution solution, Bio-Rad; secondary antibody: Alexa 488-labeled goat anti-mouse at a 1:500 dilution; Thermo Fisher) and counted manually by fluorescence microscopy (Axio observer, Zeiss). anti feline coronavirussuggested: (Acris Antibodies GmbH Cat# SM1870P, RRID:AB_981215)anti-mousesuggested: None… SciScore for 10.1101/2021.02.14.431122: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Plaques of FCoV were stained with specific antibodies (primary antibody: mouse anti feline coronavirus monoclonal antibody at 1:500 dilution solution, Bio-Rad; secondary antibody: Alexa 488-labeled goat anti-mouse at a 1:500 dilution; Thermo Fisher) and counted manually by fluorescence microscopy (Axio observer, Zeiss). anti feline coronavirussuggested: (Acris Antibodies GmbH Cat# SM1870P, RRID:AB_981215)anti-mousesuggested: NoneExperimental Models: Cell Lines Sentences Resources VeroE6 cells were seeded at 10,000 cells per well of flat bottom 96-well plates (Thermo Fisher Scientific, Roskilde VeroE6suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)Software and Algorithms Sentences Resources Covid-Organics was purchased in Madagascar. Madagascarsuggested: (Madagascar, RRID:SCR_003274)Sigmoidal dose response curves were fitted and median cytotoxic concentration (CC50) values were calculated with GraphPad Prism 8.0.0. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
